Inhibitors of brain phospholipase A2 activity: Their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders

Pharmacological Reviews

Volumn 58, Issue 3, 2006, Pages 591-620

  Farooqui, Akhlaq A ^a   Ong, Wei Yi ^b   Horrocks, Lloyd A ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 BENZYL 4 CHLOROPHENOXY)ETHYLDIMETHYL N OCTADECYLAMMONIUM CHLORIDE; 2 (2 BENZYL 4 CHLOROPHENOXY)ETHYLDIMETHYL N OCTYLAMMONIUM CHLORIDE; 3 (PYRROLE) 2 PROPIONIC ACID; [4 [3 4 (DECYLOXY)PHENOXY] 2 OXOPROPOXY]BENZOIC ACID; ALKANONE; ALPHA TOCOPHEROL; AMINE; ANTIINFLAMMATORY AGENT; ANTIMALARIAL AGENT; ARACHIDONYL TRIFLUOROMETHYL KETONE; AX 006; AX 007; AX 008; BENZAMIDINE DERIVATIVE; BENZENESULFONAMIDE DERIVATIVE; BROMOENOL LACTONE; CARBAMAZEPINE; CHLOROQUINE; CHOLINE DERIVATIVE; HYDROXYCHLOROQUINE; MEPACRINE; METHYLARACHIDONYLFLUOROPHOSPHONATE; NEUROPROTECTIVE AGENT; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; PYRROLIDINE 1; PYRROLIDINE DITHIOCARBAMATE; PYRROPHENONE; QUININE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; BRAIN INJURY; DEPRESSION; DRUG HALF LIFE; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME RELEASE; EPILEPSY; HEAD INJURY; HUMAN; IMMUNOREACTIVITY; ISCHEMIA; MULTIPLE SCLEROSIS; NERVE CELL LESION; NERVE DEGENERATION; NEUROCHEMISTRY; NEUROLOGIC DISEASE; NEUROPHARMACOLOGY; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PHYSIOLOGY; PRION DISEASE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SPINAL CORD INJURY; TOXICITY;

ANIMALS; BLOOD PROTEINS; BRAIN; BRAIN INJURIES; HUMANS; KAINIC ACID; MODELS, BIOLOGICAL; NERVOUS SYSTEM DISEASES; NEURONS; PAIN; PHOSPHOLIPASES A;

EID: 33748804968     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.58.3.7     Document Type: Review

References (303)

1. Abraham IM, Harkany T, Horvath KM, and Luiten PG (2001) Action of glucocorticoids on survival of nerve cells: promoting neurodegeneration or neuroprotection? J Neuroendocrinol 13:749-760.
2. 2. Biochim Biophys Acta 1259:125-136.
3. 2 stimulation and hydroxyl radical generation in transient cerebral ischemia. J Neurosci Res 73:308-315.
4. Adibhatla RM, Hatcher JF, and Dempsey RJ (2002) Citicoline: neuroprotective mechanisms in cerebral ischemia. J Neurochem 80:12-23.
5. 2, hydroxyl radicals, and lipid peroxidation in transient cerebral ischemia. Antioxid Redox Signal 5:647-654.
6. 2 inhibitors. Biochem Pharmacol 51:737-742.
7. Ajmone-Cat MA, Nicolini A, and Minghetti L (2003) Prolonged exposure of microglia to lipopolysaccharide modifies the intracellular signaling pathways and selectively promotes prostaglandin E-2 synthesis. J Neurochem 87:1193-1203.
8. 2α level in rat PC12 cells. Neurosci Lett 365:218-222.
9. 2. Eur J Pharmacol 326:237-250.
10. Anderle P, Farmer P, Berger A, and Roberts MA (2004) Nutrigenomic approach to understanding the mechanisms by which dietary long-chain fatty acids induce gene signals and control mechanisms involved in carcinogenesis. Nutrition 20:103-108.
11. Andersen M, Overgaard K, Meden P, and Boysen G (1999) Effects of citicoline combined with thrombolytic therapy in a rat embolic stroke model. Stroke 30:1464-1470.
12. Anderson DK, Saunders RD, Demediuk P, Dugan LL, Braughler JM, Hall ED, Means ED, and Horrocks LA (1985) Lipid hydrolysis and peroxidation in injured spinal cord: Partial protection with methylprednisolone or vitamin E and selenium. Cent Nerv Syst Trauma 2:257-267.
13. 2 mediates ischemic injury in the hippocampus: a regional difference of neuronal vulnerability. Eur J Neurosci 13:2319-2323.
14. 2γ) - roles in the membrane remodeling and activation induced by oxidative stress. J Biol Chem 278:8809-8814.
15. Ates M, Hamza M, Seidel K, Kotalla CE, Ledent C, and Guhring H (2003) Intrathecally applied flurbiprofen produces an endocannabinoid-dependent antinociception in the rat formalin test. Eur J Neurosci 17:597-604.
16. 2 augments spontaneous fatty acid release. J Biol Chem 275:18248-18258.
17. 2 which undergoes proteolytic inactivation. J Biol Chem 273:13870-13877.
18. 2 in brain. FEBS Lett 531:12-17.
19. Basselin M, Chang L, Seemann R, Bell JM, and Rapoport SI (2003) Chronic lithium administration potentiates brain arachidonic acid signaling at rest and during cholinergic activation in awake rats. J Neurochem 85:1553-1562.
20. 2 inhibitors or platelet-activating factor antagonists prevent prion replication. J Biol Chem 279:36405-36411.
21. 2 and the neurotoxicity of prions. J Gen Virol 85:3797-3804.
22. 2 is coupled to muscarinic receptors in the human astrocytoma cell line 1321N1: characterization of the transducing mechanism. Biochem J 323:281-287.
23. Beattie MS, Farooqui AA, and Bresnahan JC (2000) Review of current evidence for apoptosis after spinal cord injury. J Neurotrauma 17:915-925.
24. Ben-Ari Y and Cossart R (2000) Kainate, a double agent that generates seizures: two decades of progress. Trends Neurosci 23:580-587.
25. Berlett BS and Stadtman ER (1997) Protein oxidation in aging, disease, and oxidative stress. J Biol Chem 272:20313-20316.
26. Blackwell GJ and Flower RJ (1983) Inhibition of phospholipase. Br Med Bull 39:260-264.
27. 2 with apoptotic human T cells: role of heparan sulfate proteoglycans. FASEB J 17:1068-1080.
28. 2. Nature (Lond) 390:622-625.
29. 2 knockout mouse. J Neurochem 87:1471-1477.
30. 2) enzymes in membrane trafficking: mediators of membrane shape and function. Traffic 4:214-221.
31. 2. Eur J Pharmacol 369:373-386.
32. 2 activity in vitamin E and selenium-deficient rat lung, liver, and spleen cytosol is time-dependent and reversible. J Nutr Biochem 7:366-374.
33. 2. Biochemistry 34:15165-15174.
34. 2 at the lipid-water interface by choline derivatives that partially partition into the phospholipid bilayer. J Biol Chem 274:18864-18871.
35. Calder PC and Grimble RF (2002) Polyunsaturated fatty acids, inflammation and immunity. Eur J Clin Nutr 56:S14-S19.
36. Calon F, Lim GP, Yang FS, Morihara T, Teter B, Ubeda O, Rostaing P, Triller A, Salem NJ, Ashe KH, et al. (2004) Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 43:633-645.
37. 2 in the hippocampus. Hippocampus 8:299-309.
38. 2 isoforms: a perspective. Cell Signal 15:637-665.
39. 2 activity. Neurochem Res 23:887-892.
40. 2δ, induced in psoriatic skin. J Biol Chem 279:12890-12897.
41. 2 inhibitors. Expert Opin Ther Patents 14:937-950.
42. 2 stimulatory peptide melittin. J Biol Chem 262:4402-4406.
43. 2 after transient global forebrain ischemia in the rat. Stroke 27:527-535.
44. 2 based on a 1,3-disubstituted propan-2-one skeleton. J Med Chem 45:1348-1362.
45. Corbella B and Vieta E (2003) Molecular targets of lithium action. Acta Neuropsychiatry 15:316-340.
46. 2s in cell injury and death. J Pharmacol Exp Ther 294:793-799.
47. de Wilde MC, Leenders I, Broersen LM, Kuipers AAM, van der Beek EM, and Kiliaan AJ (2003) The omega-3 fatty acid docosahexaenoic acid (DHA) inhibits the formation of beta amyloid in CHO7PA2 cells, in Society for Neuroscience 33rd Annual Meeting Abstracts; 2003 Nov 8-12; New Orleans, LA; Abstract nr 730.11.
48. DeArmond SJ and Prusiner SB (2003) Perspectives on prion biology, prion disease pathogenesis, and pharmacologic approaches to treatment. Clin Lab Med 23:1-41.
49. 2 potentiates glutamate-induced calcium increase and cell death in primary neuronal cultures. J Neurosci Res 67:634-645.
50. Demediuk P, Saunders RD, Anderson DK, Means ED, and Horrocks LA (1985) Membrane lipid changes in laminectomized and traumatized cat spinal cord. Proc Natl Acad Sci USA 82:7071-7075.
51. Dempsey RJ and Rao VLR (2003) Cytidinediphosphocholine treatment to decrease traumatic brain injury-induced hippocampal neuronal death, cortical contusion volume, and neurological dysfunction in rats. J Neurosurg 98:867-873.
52. Denecker G, Vercammen D, Declercq W, and Vandenabeele P (2001) Apoptotic and necrotic cell death induced by death domain receptors. Cell Mol Life Sci 58:356-370.
53. Diaz-Arrastia R and Scott KS (1999) Expression of cPLA2-β and cPLA2-γ, novel paralogs of group IV cytosolic phospholipase A2 in mammalian brain. Soc Neurosci Abs 25:2206.
54. Doh-ura K, Iwaki T, and Caughey B (2000) Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol 74:4894-4897.
55. 2 and COX-2 expression during mouse colon tumorigenesis. Carcinogenesis 24:307-315.
56. 2. Biochim Biophys Acta 876:639-645.
57. Dubin NH, Blake DA, DiBlasi MC, Parmley TH, and King TM (1982) Pharmacokinetic studies on quinacrine following intrauterine administration to cynomolgus monkeys. Fertil Steril 38:735-740.
58. 2 in brain during ischemia. J Neurochem 39:1111-1116.
59. Endres S and von Schacky C (1996) n-3 polyunsaturated fatty acids and human cytokine synthesis. Curr Opin Lipidol 7:48-52.
60. 2 inhibitor, quinacrine, reduces infarct size in rats after transient middle cerebral artery occlusion. Brain Res 752:203-208.
61. 2 signaling in the nucleus. Brain Res Rev 45:179-195.
62. Farooqui AA, Haun SE, and Horrocks LA (1994a) Ischemia and hypoxia, in Basic Neurochemistry (Siegel GJ, Agranoff BW, Albers RW, and Molinoff PB eds) pp 867-883, Raven Press, New York.
63. Farooqui AA and Horrocks LA (1991) Excitatory amino acid receptors, neural membrane phospholipid metabolism and neurological disorders. Brain Res Rev 16:171-191.
64. Farooqui AA and Horrocks LA (1994) Excitotoxicity and neurological disorders: involvement of membrane phospholipids. Int Rev Neurobiol 36:267-323.
65. Farooqui AA and Horrocks LA (2001) Plasmalogens: workhorse lipids of membranes in normal and injured neurons and glia. Neuroscientist 7:232-245.
66. Farooqui AA and Horrocks LA (2004a) Beneficial effects of docosahexaenoic acid on health of the human brain. Agro Food Ind Hi-Tech 15:52-53.
67. Farooqui AA and Horrocks LA (2004b) Plasmalogens, platelet activating factor, and other ether lipids, in Bioactive Lipids (Nicolaou A and Kokotos G eds) pp 107-134, Oily Press, Bridgwater, UK.
68. Farooqui AA, Horrocks LA, and Farooqui T (2000a) Deacylation and reacylation of neural membrane glycerophospholipids. J Mol Neurosci 14:123-135.
69. 2 activity: their neurochemical effects and therapeutical importance for neurological disorders. Brain Res Bull 49:139-153.
70. Farooqui AA, Ong WY, and Horrocks LA (2003a) Plasmalogens, docosahexaenoic acid, and neurological disorders, in Peroxisomal Disorders and Regulation of Genes (Roels F, Baes M, and de Bies S eds) pp 335-354, Kluwer Academic/Plenum Publishers, London.
71. Farooqui AA, Ong WY, and Horrocks LA (2003b) Stimulation of lipases and phospholipases in Alzheimer disease, in Nutrition and Biochemistry of Phospholipids (Szuhaj B and van NieuwenhuyzenWeds) pp 14-29, AOCS Press, Champaign, IL.
72. 2 inhibitors in kainic acid-induced neurodegeneration. Curr Drug Targets Cardiovasc Haematol Disord 4:85-96.
73. 2: Localization, role, and involvement in neurological diseases. Neuroscientist 6:169-180.
74. 2 inhibitors. Brain Res Rev 38:61-78.
75. 2 inhibitors as therapeutic agents for neural cell injury. Curr Med Chem - Anti-Inflammatory & Anti-Allergy Agents 1:193-204.
76. Farooqui AA, Pendley CE II, Taylor WA, and Horrocks LA (1985) Studies on diacylglycerol lipases and lysophospholipases of bovine brain, in Phospholipids in the Nervous System, Vol. II: Physiological Role (Horrocks LA, Kanfer JN, and Porcellati G eds) pp 179-192, Raven Press, New York.
77. Farooqui AA, Rapoport SI, and Horrocks LA (1997a) Membrane phospholipid alterations in Alzheimer disease: deficiency of ethanolamine plasmalogens. Neurochem Res 22:523-527.
78. Farooqui AA, Rosenberger TA, and Horrocks LA (1997b) Arachidonic acid, neurotrauma, and neurodegenerative diseases, in Handbook of Essential Fatty Acid Biology (Yehuda S and Mostofsky DI eds) pp 277-295, Humana Press, Totowa, NJ.
79. Farooqui AA, Yang H-C, and Horrocks LA (1994b) Purification of lipases, phospholipases and kinases by heparin-Sepharose chromatography. J Chromatogr 673:149-158.
80. 2, and signal transduction. Brain Res Rev 21:152-161.
81. 2 in neurodegeneration. Neurochem Int 30:517-522.
82. 2 and its role in brain tissue. J Neurochem 69:889-901.
83. Farrelly PV, Kenna BL, Laohachai KL, Bahadi R, Salmona M, Forloni G, and Kourie JI (2003) Quinacrine blocks PrP (106-126)-formed channels. J Neurosci Res 74:934-941.
84. Fernando SR and Pertwee RG (1997) Evidence that methyl arachidonyl fluorophosphate is an irreversible cannabinoid receptor antagonist. Br J Pharmacol 121:1716-1720.
85. Ferrari G, Batistatou A, and Greene LA (1993) Gangliosides rescue neuronal cells from death after trophic factor deprivation. J Neurosci 13:1879-1887.
86. Fighera MR, Bonini JS, Frussa R, Dutra CS, Hagen MEK, Rubin MA, and Mello CF (2004) Monosialoganglioside increases catalase activity in cerebral cortex of rats. Free Radic Res 38:495-500.
87. 2 inhibitor. Dev Brain Res 78:81-86.
88. Follette P (2003) New perspectives for prion therapeutics meeting: prion disease treatment's early promise unravels. Science (Wash DC) 299:191-192.
89. Friguet B, Stadtman ER, and Szweda LI (1994) Modification of glucose-6-phosphate dehydrogenase by 4-hydroxy-2-nonenal. J Biol Chem 269:21639-21643.
90. 2. J Biol Chem 278:44683-44690.
91. 2 inhibitor in rat hippocampal slices. Br J Pharmacol 132:1417-1422.
92. 2 inhibitor impairs spatial memory of mice. Jpn J Pharmacol 83:277-278.
93. Gamoh S, Hashimoto M, Sugioka K, Hossain MS, Hata N, Misawa Y, and Masumura S (1999) Chronic administration of docosahexaenoic acid improves reference memory-related learning ability in young rats. Neuroscience 93:237-241.
94. 2 activity in Alzheimer brains. Biol Psychiatry 37:13-17.
95. 2 activity in Alzheimer's disease and mild cognitive impairment. J Neural Transm 111:591-601.
96. Geddes JW, Ulas J, Brunner LC, Choe W, and Cotman CW (1992) Hippocampal excitatory amino acid receptors in elderly, normal individuals and those with Alzheimer's disease: non-N-methyl-D-aspartate receptors. Neuroscience 50:23-34.
97. Geisler FH, Dorsey FC, and Coleman WP (1991) Recovery of motor function after spinal-cord injury - a randomized, placebo-controlled trial with GM-1 ganglioside. N Engl J Med 324:1829-1887.
98. 2 expression and cyclooxygenase activity in rat brain. Biol Psychiat 56:248-254.
99. 2α blocks arachidonic acid release in a variety of mammalian cells. Biochim Biophys Acta 1513:160-166.
100. Ginsberg L, Xuereb JH, and Gershfeld NL (1998) Membrane instability, plasmalogen content, and Alzheimer's disease. J Neurochem 70:2533-2538.
101. 2 by phosphorylation in rat mesangial cells. J Clin Investig 93:1224-1233.
102. Grossman A, Zeiler B, and Sapirstein V (2003) Prion protein interactions with nucleic acid: possible models for prion disease and prion function. Neurochem Res 28:955-963.
103. Guan ZZ, Wang YA, Cairns NJ, Lantos PL, Dallner G, and Sindelar PJ (1999) Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. J Neuropathol Exp Neurol 58:740-747.
104. Guentchev M, Voigtlander T, Haberler C, Groschup MH, and Budka H (2000) Evidence for oxidative stress in experimental prion disease. Neurobiol Dis 7:270-273.
105. Hamano H, Nabekura J, Nishikawa M, and Ogawa T (1996) Docosahexaenoic acid reduces GABA response in substantia nigra neuron of rat. J Neurophysiol 75:1264-1270.
106. 2α activity that is responsible for arachidonic acid release. J Biol Chem 278:24153-24163.
107. Han XL, Holtzman DM, and McKeel DW Jr (2001) Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J Neurochem 77:1168-1180.
108. 2. Prostaglandins Other Lipid Mediat 68-69:71-82.
109. Hannon GJ (2002) RNA interference. Nature (Lond) 418:244-251.
110. Hashimoto M, Hossain S, Shimada T, Sugioka K, Yamasaki H, Fujii Y, Ishibashi Y, Oka JI, and Shido O (2002) Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer's disease model rats. J Neurochem 81:1084-1091.
111. 2: implications for the coordinated regulation of phospholipolysis and glycolysis. J Biol Chem 268:9892-9900.
112. 2 and the distinct transcriptional programs of astrocytoma cells. Trends Neurosci 23:259-264.
113. 2. Biol Pharm Bull 27:1168-1173.
114. 2. Biochim Biophys Acta 1488:124-138.
115. 2 from bovine brain cytosol. J Neurochem 59:708-714.
116. Min-induced tumorigenesis. Proc Natl Acad Sci USA 98:3935-3939.
117. Hong S, Gronert K, Devchand PR, Moussignac RL, and Serhan CN (2003) Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells - autacoids in anti-inflammation. J Biol Chem 278:14677-14687.
118. Horrobin DF (2003) Eicosapentaenoic acid derivatives in the management of schizophrenia, in Phospholipid Spectrum Disorders in Psychiatry and Neurology (Peet M, Glen L, and Horrobin DF eds) pp 371-376, Marius Press, Carnforth, Lancashire, UK.
119. Horrocks LA, Demediuk P, Saunders RD, Dugan L, Clendenon NR, Means ED, and Anderson DK (1985) The degradation of phospholipids, formation of metabolites of arachidonic acid, and demyelination following experimental spinal cord injury. Cent Nerv Syst Trauma 2:115-120.
120. Horrocks LA and Farooqui AA (2004) Docosahexaenoic acid in the diet: its importance in maintenance and restoration of neural membrane function. Prostaglandins Leukotrienes Essent Fatty Acids 70:361-372.
121. Hossain MS, Hashimoto M, Gamoh S, and Masumura S (1999) Antioxidative effects of docosahexaenoic acid in the cerebrum versus cerebellum and brainstem of aged hypercholesterolemic rats. J Neurochem 72:1133-1138.
122. Hossain MS, Hashimoto M, and Masumura S (1998) Influence of docosahexaenoic acid on cerebral lipid peroxide level in aged rats with and without hypercholesterolemia. Neurosci Lett 244:157-160.
123. 2 associated with schizophrenia. Schizophr Res 21:111-116.
124. 2 in post-mortem white matter from patients with multiple sclerosis. Neurochem Res 20:1335-1343.
125. Ibuki T, Matsumura K, Yamazaki Y, Nozaki T, Tanaka Y, and Kobayashi S (2003) Cyclooxygenase-2 is induced in the endothelial cells throughout the central nervous system during carrageenan-induced hind paw inflammation; its possible role in hyperalgesia. J Neurochem 86:318-328.
126. James MJ, Gibson RA, and Cleland LG (2000) Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 71:343S-348S.
127. +-ATPase activity by oxygen free radicals. NeuroReport 7:333-337.
128. Jeffrey M, Goodsir CM, Bruce ME, McBride PA, Scott JR, and Halliday WG (1992) Infection specific prion protein (PrP) accumulates on neuronal plasmalemma in scrapie infected mice. Neurosci Lett 147:106-109.
129. Junqueira R, Cordeiro Q, Meira-Lima I, Gattaz WF, and Vallada H (2004) Allelic association analysis of phospholipase A2 genes with schizophrenia. Psychiatr Genet 14:157-160.
130. 2 phosphorylation, translocation, proteolysis and activation by tumour necrosis factor-receptor subtypes. Biochem J 374:453-461.
131. 2+-dependent regulators of membrane function. News Physiol Sci 10:171-176.
132. Kajiwara K, Nagawawa H, Shimizu-Nishikawa S, Ookuri T, Kimura M, and Sugaya E (1996) Molecular characterization of seizure-related genes isolated by differential screening. Biochem Biophys Res Commun 219:795-799.
133. 2 plays a key role in the pathogenesis of multiple sclerosis-like disease. Neuron 41:323-335.
134. Kanfer JN, Sorrentino G, and Sitar DS (1998) Phospholipases as mediators of amyloid β-peptide neurotoxicity: an early event contributing to neurodegeneration characteristic of Alzheimer's disease. Neurosci Lett 257:93-96.
135. Katsuki H and Okuda S (1995) Arachidonic acid as a neurotoxic and neurotrophic substance. Prog Neurobiol 46:607-636.
136. 2 in brain cortical cultures. Biochem J 310:83-90.
137. 2 messenger RNA mainly in neurons in the rat brain. Neuroscience 92:1061-1077.
138. 2 are resistant to MPTP neurotoxicity. J Neurochem 71:2634-2637.
139. Kobayashi Y, Hirata K, Tanaka H, and Yamada T (2003) Quinacrine administration to a patient with Creutzfeldt-Jakob disease who received a cadaveric dura mater graft - an EEG evaluation. Rinsho Shinkeigaku 43:403-408.
140. 2 by novel 2-oxoamides in vitro, in cells, and in vivo. J Med Chem 47:3615-3628.
141. 2 and glutamate on inducing cell death and sustained arachidonic acid metabolic changes in primary cortical neuronal cultures. J Biol Chem 271:32722-32728.
142. 2-mediated neuronal cell death involves glutamate ionotropic receptors. NeuroReport 13:1963-1966.
143. Korth C, May BC, Cohen FE, and Prusiner SB (2001) Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci USA 98:9836-9841.
144. Kramer BC, Yabut JA, Cheong J, Jnobaptiste R, Robakis T, Olanow CW, and Mytilineou C (2004) Toxicity of glutathione depletion in mesencephalic cultures: a role for arachidonic acid and its lipoxygenase metabolites. Eur J Neurosci 19:280-286.
145. 2 mediates neuronal apoptosis induced by soluble oligomers of the amyloid-β peptide. FASEB J 19:85-87.
146. 2 antagonist, induces dispersal of both Golgi stack- and trans Golgi network-resident proteins throughout the cytoplasm. Biochem Biophys Res Commun 281:582-588.
147. 2 activation: the involvement of MAP kinases. J Neurochem 86:980-991.
148. 2: an antisense oligonucleotide having a nuclear localization binds a C-terminal motif of glyceraldehyde-3-phosphate dehydrogenase. Biochim Biophys Acta 1636:129-135.
149. 2 and their effect on enzyme activity. J Biol Chem 273:207-214.
150. Laruelle M, Abi-Dargham A, Gil R, Kegeles L, and Innis R (1999) Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 46:56-72.
151. Latorre E, Collado MP, Fernández I, Aragonés MD, and Catalán RE (2003) Signaling events mediating activation of brain ethanolamine plasmalogen hydrolysis by ceramide. Eur J Biochem 270:36-46.
152. Lazarewicz JW, Wroblewski JT, and Costa E (1990) N-Methyl-D-aspartate- sensitive glutamate receptors induce calcium-mediated arachidonic acid release in primary cultures of cerebellar granule cells. J Neurochem 55:1875-1881.
153. 2. Arch Pharm (Weinheim) 329:483-488.
154. 2: variation of the alkanoic acid substituent, the acyl chain and the position of the pyrrole nitrogen. Eur J Med Chem 32:805-814.
155. 2. J Med Chem 40:2694-2705.
156. 2 by amyloid β-peptides in vitro. Biochemistry 35:9407-9414.
157. Lerma J (1997) Kainate reveals its targets. Neuron 19:1155-1158.
158. Leslie CC (2004) Regulation of arachidonic acid availability for eicosanoid production. Biochem Cell Biol 82:1-17.
159. 2 in reactive astrocytes in response to transient focal cerebral ischemia in the rat brain. J Neurochem 90:637-645.
160. 2. J Biol Chem 271:6010-6016.
161. Lonergan PE, Martin DSD, Horrobin DF, and Lynch MA (2004) Neuroprotective actions of eicosapentaenoic acid on lipopolysaccharide-induced dysfunction in rat hippocampus. J Neurochem 91:20-29.
162. Love R (2001) Old drugs to treat new variant Creutzfeldt-Jakob disease. Lancet 358:563.
163. 2) and hydroxynonenal (HNE) in neurons of the lateral septum following fimbria-fornix transection. Exp Brain Res 138:500-508.
164. 2 inhibitors on kainate-induced neuronal injury in rat hippocampal slices. Free Radic Biol Med 30:1263-1273.
165. Lukácová N, Halát G, Chavko M, and Maršala J (1996) Ischemia-reperfusion injury in the spinal cord of rabbits strongly enhances lipid peroxidation and modifies phospholipid profiles. Neurochem Res 21:869-873.
166. 2 under reduced membrane potential. J Biol Chem 279:37860-37869.
167. Mandal PK and Pettegrew JW (2004) Alzheimer's disease: NMR studies of asialo (GM1) and trisialo (GT1b) ganglioside interactions with A β(1-40) peptide in a membrane mimic environment. Neurochem Res 29:447-453.
168. Marcheselli VL, Hong S, Lukiw WJ, Tian XH, Gronert K, Musto A, Hardy M, Gimenez JM, Chiang N, Serhan CN, et al. (2003) Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem 278:43807-43817.
169. 2 from rat neuronal cells and its possible function in the regulation of catecholamine secretion. Biochem J 318:701-709.
170. May BCH, Fafarman AT, Hong SB, Rogers M, Deady LW, Prusiner SB, and Cohen FE (2003) Potent inhibition of scrapie prion replication in cultured cells by bisacridines. Proc Natl Acad Sci USA 100:3416-3421.
171. Mazière C, Conte MA, Degonville J, Ali D, and Mazière JC (1999) Cellular enrichment with polyunsaturated fatty acids induces an oxidative stress and activates the transcription factors AP1 and NFκB. Biochem Biophys Res Commun 265:116-122.
172. McIntosh TK, Saatman KE, Raghupathi R, Graham DI, Smith DH, Lee VM, and Trojanowski JQ (1998) The molecular and cellular sequelae of experimental traumatic brain injury: pathogenetic mechanisms. Neuropathol Appl Neurobiol 24:251-267.
173. 2 and transglutaminase. J Clin Investig 111:19-21.
174. 2 and transglutaminase. J Clin Investig 111:19-21.
175. Milhavet O, McMahon HE, Rachidi W, Nishida N, Katamine S, Mange A, Arlotto M, Casanova D, Riondel J, Favier A, et al. (2000) Prion infection impairs the cellular response to oxidative stress. Proc Natl Acad Sci USA 97:13937-13942.
176. Mir C, Clotet J, Aledo R, Durany N, Argemi J, Lozano R, Cervos-Navarro J, and Casals N (2003) CDP-choline prevents glutamate-mediated cell death in cerebellar granule neurons. J Mol Neurosci 20:53-59.
177. 2 are expressed in rat brain. Neurosci Lett 258:139-142.
178. 2 binds with high affinity and specificity to phosphatidylinositol 4,5-bisphosphate resulting in dramatic increases in activity. J Biol Chem 273:2184-2191.
179. 2α, cyclic AMP and ATP. J Neurochem 41:1576-1586.
180. Mukherjee PK, Marcheselli VL, Serhan CN, and Bazan NG (2004) Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci USA 101:8491-8496.
181. Muller WEG, Ushijima H, Schroder HC, Forrest JMS, Schatton WFH, Rytik PG, and Heffner-Lauc M (1993) Cytoprotective effect of NMDA receptor antagonists on prion protein (PrionSc)-induced toxicity in rat cortical cell cultures. Eur J Pharmacol 246:261-267.
182. 2. Crit Rev Immunol 17:225-283.
183. Murphy EJ and Horrocks LA (1993) CDPcholine, CDPethanolamine, lipid metabolism and disorders of the central nervous system, in Phospholipids and Signal Transmission (Massarelli R, Horrocks L, Kanfer JN, and Löffelholz K eds) pp 353-372, Springer-Verlag GmbH, Heidelberg.
184. 2 induce neurite outgrowth in PC12 cells. Biochem J 376:655-666.
185. Ng CH and Ong WY (2001) Increased expression of γ-aminobutyric acid transporters GAT-1 and GAT-3 in the spinal trigeminal nucleus after facial carrageenan injections. Pain 92:29-40.
186. Nordvik I, Myhr KM, Nyland H, and Bjerve KS (2000) Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients. Acta Neurol Scand 102:143-149.
187. 2α) by gas chromatography-mass spectrometry-selected ion monitoring for medical samples. J Chromatogr B 792:131-140.
188. 2 inhibitors. J Med Chem 34:2260-2267.
189. Ong WY, He Y, Suresh S, and Patel S (1997) Differential expression of apoD and apoE in the kainate lesioned rat hippocampus. Neuroscience 79:359-367.
190. Ong WY, Hu CY, Hjelle OP, Ottersen OP, and Halliwell B (2000) Changes in glutathione in the hippocampus of rats injected with kainate: depletion in neurons and upregulation in glia. Exp Brain Res 132:510-516.
191. Ong WY, Ling SF, Yeo JF, Chiueh CC, and Farooqui AA (2005) Injury and recovery of pyramidal neurons in the rat hippocampus after a single episode of oxidative stress induced by intracerebroventricular injection of ferrous ammonium citrate. Reprod Nutr Dev 45:647-662.
192. 2 and neuronal death after intracerebroventricular carrageenan injection, and neuroprotective effects of quinacrine. Exp Neurol 183:449-457.
193. 2 mRNA levels in the rat hippocampus after kainate-induced neuronal injury. Exp Brain Res 148:521-524.
194. Ong WY, Ren MQ, Makjanic J, Lim TM, and Watt F (1999) A nuclear microscopic study of elemental changes in the rat hippocampus after kainate-induced neuronal injury. J Neurochem 72:1574-1579.
195. 2α, pyrrophenone. Biochem J 363:727-735.
196. Ortiz GG, Sánchez-Ruiz MY, Tan DX, Reiter RJ, Benítez-King G, and Beas-Zárate C (2001) Melatonin, vitamin E, and estrogen reduce damage induced by kainic acid in the hippocampus: potassium-stimulated GABA release. J Pineal Res 31:62-67.
197. 2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes. Arch Toxicol 73:1-6.
198. 2 gene and mood disorders in the Korean population. Neuropsychobiology 49:185-188.
199. 2-released arachidonic acid. Free Radic Biol Med 36:319-329.
200. 2 and cyclooxygenase-2 in rhesus monkey cerebellum. Mol Brain Res 116:106-114.
201. Peet M and Ryles S (2001) Eicosapentaenoic acid - a potential new treatment for schizophrenia?, in Fatty Acids: Physiological and Behavioral Functions (Mostofsky DI, Yehuda S, and Salem N eds) pp 345-356, Humana Press Inc, Totowa, NJ.
202. Pentland AP, Morrison AR, Jacobs SC, Hruza LL, Hebert JS, and Packer L (1992) Tocopherol analogs suppress arachidonic acid metabolism via phospholipase inhibition. J Biol Chem 267:15578-15584.
203. 2 in arachidonic acid release, phospholipid fatty acid incorporation, and apoptosis in U937 cells responding to hydrogen peroxide. J Biol Chem 279:40385-40391.
204. Perovic S, Pergande G, Ushijima H, Kelve M, Forrest J, and Muller WEG (1995) Flupirtine partially prevents neuronal injury induced by prion protein fragment and lead acetate. Neurodegeneration 4:369-374.
205. Pettegrew JW (1989) Molecular insights into Alzheimer disease. Ann NY Acad Sci 568:5-28.
206. Pettegrew JW, Klunk WE, Kanal E, Panchalingam K, and McClure RJ (1995) Changes in brain membrane phospholipid and high-energy phosphate metabolism precede dementia. Neurobiol Aging 16:973-975.
207. Pettegrew JW, Panchalingam K, Hamilton RL, and McClure RJ (2001) Brain membrane phospholipid alterations in Alzheimer's disease. Neurochem Res 26:771-782.
208. 2. J Biol Chem 279:11320-11326.
209. Peyrin JM, Lasmezas CI, Haik S, Tagliavini F, Salmona M, Williams A, Richie D, Deslys JP, and Dormont D (1999) Microglial cells respond to amyloidogenic PrP peptide by the production of inflammatory cytokines. NeuroReport 10:723-729.
210. Phillis JW and O'Regan MH (2004) A potentially critical role of phospholipases in central nervous system ischemic, traumatic, and neurodegenerative disorders. Brain Res Rev 44:13-47.
211. 2. J Biol Chem 274:8823-8831.
212. 2 inhibitors suppress central nervous system inflammation. Glia 44:275-282.
213. 2. Cell Death Differ 6:890-901.
214. 2 from rabbit kidney. J Biol Chem 271:15451-15457.
215. Prusiner SB (2001) Shattuck lecture - Neurodegenerative diseases and prions. N Engl J Med 344:1516-1526.
216. 2 activation and arachidonic acid release in unanesthetized rats. Brain Res Brain Res Protoc 12:16-25.
217. 2-mediated signal transduction in response to acute fluoxetine administration in unanesthetized rats. Neuropsychopharmacology 28:1219-1226.
218. Rao AM, Hatcher JF, and Dempsey RJ (2001) Does CDP-choline modulate phospholipase activities after transient forebrain ischemia? Brain Res 893:268-272.
219. Rapoport SI (1999) In vivo fatty acid incorporation into brain phospholipids in relation to signal transduction and membrane remodeling. Neurochem Res 24:1403-1415.
220. Ray P, Ray R, Broomfield CA, and Berman JD (1994) Inhibition of bioenergetics alters intracellular calcium, membrane composition, and fluidity in a neuronal cell line. Neurochem Res 19:57-63.
221. 2, blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets. J Biochem 269:15619-15624.
222. 2 is a target for chronic lithium in rat brain. NeuroReport 10:3887-3890.
223. 2) activity in gerbil brain: enhanced activities of cytosolic, mitochondrial, and microsomal forms after ischemia and reperfusion. J Neurosci 11:1829-1836.
224. Rosales-Corral S, Tan DX, Reiter RJ, Valdivia-Velázquez M, Acosta-Martínez JP, and Ortiz GG (2004) Kinetics of the neuroinflammation-oxidative stress correlation in rat brain following the injection of fibrillar amyloid-β onto the hippocampus in vivo. J Neuroimmunol 150:20-28.
225. 2 knockout mouse. J Lipid Res 44:109-117.
226. Rosenberger TA, Villacreses NE, Hovda JT, Bosetti F, Weerasinghe G, Wine RN, Harry GJ, and Rapoport SI (2004) Rat brain arachidonic acid metabolism is increased by a 6-day intracerebral ventricular infusion of bacterial lipopolysaccharide. J Neurochem 88:1168-1178.
227. 2-associated processes in the human brain and their role in neuropathology and psychopathology, in Phospholipid Spectrum Disorders in Psychiatry and Neurology (Peet M, Glen L, and Horrobin DF eds) pp 163-182, Marius Press, Carnforth, Lancashire, UK.
228. 2. Arch Gen Psychiatry 54:487-494.
229. 2 activity in human brain. J Neurochem 64:2213-2221.
230. 2 activity in rat brain striatum. Prostaglandins Leukotrienes Essent Fatty Acids 66:479-483.
231. 2 activities in brain of patients with schizophrenia. Brain Res 821:407-413.
232. 2 gene polymorphism in schizophrenia using eye movement disturbances as an endophenotypic marker. Neuropsychobiology 47:115-119.
233. Salvati S, Natali F, Attorri L, Raggi C, Di Biase A, and Sanchez M (2004) Stimulation of myelin proteolipid protein gene expression by eicosapentaenoic acid in C6 glioma cells. Neurochem Int 44:331-338.
234. 2 and cyclooxygenase-2 in thea hippocampus after kainate lesions. Brain Res 788:223-231.
235. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman DW, Pfeiffer E, et al. (1997) A controlled trial of selegiline, α-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 336:1216-1222.
236. 2 in ischemic and toxic brain injury. Neurochem Res 25:745-753.
237. Schapira AH (1996) Oxidative stress and mitochondrial dysfunction in neurodegeneration. Curr Opin Neurol 9:260-264.
238. 2 enzymes as therapeutic targets. Expert Opin Ther Targets 7:427-440.
239. 2 expression by sterol availability. Biochim Biophys Acta 1684:29-37.
240. 2. J Med Chem 43:1041-1044.
241. Serhan CN, Gotlinger K, Hong S, and Arita M (2004) Resolvins, docosatrienes, and neuroprotectins, novel ω-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis. Prostaglandins Other Lipid Mediat 73:155-172.
242. Shanker G and Aschner M (2003) Methylmercury-induced reactive oxygen species formation in neonatal cerebral astrocytic cultures is attenuated by antioxidants. Mol Brain Res 110:85-91.
243. 2 expression in primary neuronal cultures. Neurotoxicology 25:399-406.
244. Shin EJ, Jhoo JH, Kim WK, Jhoo WK, Lee C, Jung BD, and Kim HC (2004) Protection against kainate neurotoxicity by pyrrolidine dithiocarbamate. Clin Exp Pharmacol Physiol 31:320-326.
245. 2 activity is required for nuclear shrinkage in caspase-independent cell death. J Cell Biol 163:1219-1230.
246. 2 subtypes in rat cerebellum. J Neurocytol 33:297-307.
247. 2 is activated after experimental closed head injury in the rat. J Neurochem 53:1541-1546.
248. Singer TP, Castagnoli N Jr, Ramsay RR, and Trevor AJ (1987) Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. J Neurochem 49:1-8.
249. 2-derived arachidonic acid and its metabolites. Brain Res 721:39-48.
250. 2-β. J Biol Chem 274:17063-17067.
251. 2 inhibitors selectively increases AMPA receptor-mediated synaptic transmission. Hippocampus 14:319-325.
252. 2) immunoreactivity is elevated in Alzheimer's disease brain. Neurobiol Dis 3:51-63.
253. 2 is induced in reactive glia following different forms of neurodegeneration. Glia 27:110-128.
254. Stewart LR, White AR, Jobling MF, Needham BE, Maher F, Thyer J, Beyreuther K, Masters CL, Collins SJ, and Cappai R (2001) Involvement of the 5-lipoxygenase pathway in the neurotoxicity of the prion peptide PrP106-126. J Neurosci Res 65:565-572.
255. Stone SJ, Cui Z, and Vance JE (1998) Cloning and expression of mouse liver phosphatidylserine synthase-1 cDNA - overexpression in rat hepatoma cells inhibits the CDP-ethanolamine pathway for phosphatidylethanolamine biosynthesis. J Biol Chem 273:7293-7302.
256. 2. Biochemistry 32:5935-5940.
257. 2+. Br J Pharmacol 139:1014-1022.
258. Sugaya K, Uz T, Kumar V, and Manev H (2000) New anti-inflammatory treatment strategy in Alzheimer's disease. Jpn J Pharmacol 82:85-94.
259. 2 in the central nervous system: implications for neurodegenerative diseases. J Lipid Res 45:205-213.
260. Svennerholm L (1994) Gangliosides-a new therapeutic agent against stroke and Alzheimer's disease. Life Sci 55:2125-2134.
261. 2 are less susceptible to cerebral ischemia/reperfusion injury, in Brain Edema XII (Kuroiwa T, Baethmann A, Czernicki Z, Hoff JT, Ito U, Katayama Y, Mararou A, Mendelow AD, and Reulen HJ eds) pp 169-172, Springer-Verlag Wien, Vienna.
262. Tagami M, Ikeda K, Yamagata K, Nara Y, Fujino H, Kubota A, Numano F, and Yamori Y (1999) Vitamin E prevents apoptosis in hippocampal neurons caused by cerebral ischemia and reperfusion in stroke-prone spontaneously hypertensive rats. Lab Invest 79:609-615.
263. Tariq M, Khan HA, Al Moutaery K, and Al Deeb S (2001) Protective effect of quinacrine on striatal dopamine levels in 6-OHDA and MPTP models of Parkinsonism in rodents. Brain Res Bull 54:77-82.
264. Taylor WA (1988) Effects of Impact Injury of Rat Spinal Cord on Activities of Some Enzymes of Lipid Hydrolysis. Doctoral Dissertation, The Ohio State University, Columbus, OH.
265. Terano T, Fujishiro S, Ban T, Yamamoto K, Tanaka T, Noguchi Y, Tamura Y, Yazawa K, and Hirayama T (1999) Docosahexaenoic acid supplementation improves the moderately severe dementia from thrombotic cerebrovascular diseases. Lipids 34 (Suppl):S345-S346.
266. 2 activity in the normal and kainate injected rat brain, and inhibition by a peptide derived from python serum. Exp Brain Res 150:427-433.
267. 2 in immortalized astrocytes (DITNC). J Mol Neurosci 12:89-99.
268. 2 activity in rat heart myoblastic cells. Biochem J 319:385-391.
269. 2 activation in rat vascular smooth muscle via extracellular signal-regulated kinases pathway. Biochem Pharmacol 64:425-431.
270. 2 plays an important role in myelin breakdown and phagocytosis during Wallerian degeneration. Mol Cell Neurosci 24:753-765.
271. 2. Biochemistry 32:12560-12565.
272. Turnbull S, Tabner BJ, Brown DR, and Allsop D (2003) Quinacrine acts as an antioxidant and reduces the toxicity of the prion peptide PrP106-126. NeuroReport 14:1743-1745.
273. 2α as revealed by gene-targeted mice. Prostaglandins Other Lipid Mediat 68-69:59-69.
274. Vanags DM, Larsson P, Feltenmark S, Jakobsson PJ, Orrenius S, Claesson HE, and Aguilar-Santelises M (1997) Inhibitors of arachidonic acid metabolism reduce DNA and nuclear fragmentation induced by TNF plus cycloheximide in U937 cells. Cell Death Differ 4:479-486.
275. Visioli F, Rodriguez de Turco EB, Kreisman NR, and Bazan NG (1994) Membrane lipid degradation is related to interictal cortical activity in a series of seizures. Metab Brain Dis 9:161-170.
276. Vogtherr M, Grimme S, Elshorst B, Jacobs DM, Fiebig K, Griesinger C, and Zahn R (2003) Antimalarial drug quinacrine binds to C-terminal helix of cellular prion protein. J Med Chem 46:3563-3564.
277. Walsh DM and Selkoe DJ (2004) Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44:181-193.
278. Walters ET (1994) Injury-related behavior and neuronal plasticity: an evolutionary perspective on sensitization, hyperalgesia, and analgesia. Int Rev Neurobiol 36:325-427.
279. Wang TG, Qin L, Liu B, Liu YX, Wilson B, Eling TE, Langenbach R, Taniura S, and Hong JS (2004a) Role of reactive oxygen species in LPS-induced production of prostaglandin E-2 in microglia. J Neurochem 88:939-947.
280. 2 in IL-1β and IL-6 release in LPS-induced HeLa cells. Cell Biochem Funct 22:41-44.
281. Wang ZG (2003) Role of redox state in modulation of ion channel function by fatty acids and phospholipids. Br J Pharmacol 139:681-683.
282. 2 or lipoxygenase/cytochrome P450 pathways. Brain Res Bull 63:485-489.
283. Wei EP, Lamb RG, and Kontos HA (1982) Increased phospholipase C activity after experimental brain injury. J Neurosurg 56:695-698.
284. 2 on neurotransmitter release. Neuroscience 121:891-898.
285. Wells K, Farooqui AA, Liss L, and Horrocks LA (1995) Neural membrane phospholipids in Alzheimer disease. Neurochem Res 20:1329-1333.
286. 2. FEBS Lett 377:358-362.
287. 2. J Biol Chem 269:3117-3124.
288. 2. Free Radic Biol Med 34:1531-1543.
289. 2 products retain a neuron specific γ isoform of PKC on the plasma membrane through the C1 domain - a molecular mechanism for sustained enzyme activity. Neurochem Int 45:39-47.
290. 2 from bovine brain. Biochem J 299:91-95.
291. 2 from bovine brain. Biochem Biophys Res Commun 199:1158-1166.
292. 2 from rat brain. J Neurochem 73:1278-1287.
293. Yao JK and Van Kammen DP (2004) Membrane phospholipids and cytokine interaction in schizophrenia, in Disorders of Synaptic Plasticity and Schizophrenia (Smythies J ed) pp 297-326, Academic Press, San Diego, CA.
294. Yao JK, Leonard S, and Reddy RD (2000) Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr Res 42:7-17.
295. 2 and phospholipids in neural membranes in an experimental epilepsy model. Acta Neurol Scand 106:258-262.
296. 2 inhibitors modulates allodynia after facial carrageenan injection in mice. Pain 112:148-155.
297. 2-linked cascade in signaling by an oncogenic, constitutively active Ha-Ras isoform. J Biol Chem 276:24645-24653.
298. 2 from cytosol to membranes in rat brain induced by calcium ions. Biochem Biophys Res Commun 170:484-490.
299. 2 activity in rat brain. Biochem Biophys Res Commun 185:350-355.
300. 2 in cell death induced by 1-methyl-4-phenylpyridinium ion, a dopaminergic neurotoxin, in GH3 cells. Brain Res 855:244-251.
301. 2 isoforms in rat striatal astrocytes. Neurosci Lett 247:83-86.
302. Zhang B, Tanaka J, Yang L, Yang L, Sakanaka M, Hata R, Maeda N, and Mitsuda N (2004) Protective effect of vitamin E against focal brain ischemia and neuronal death through induction of target genes of hypoxia-inducible factor-1. Neuroscience 126:433-440.
303. Zhao Y, Joshi-Barve S, Barve S, and Chen LH (2004) Eicosapentaenoic acid prevents LPS-induced TNF-α expression by preventing NF-κB activation. J Am Coll Nutr 23:71-78.